Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention
- Conditions
- Kidney DiseasesCoronary AngiographyCoronary Artery DiseaseMetabolic SyndromeCardio-Renal Syndrome
- Registration Number
- NCT04407936
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Brief Summary
As a single center, retrospective observation study in Guangdong Institute of Cardiovascular Diseases, this study included the main study population of patients who underwent coronary angiography and / or coronary intervention from January 2007 to Decemeber 2018. The hospitalization information was collected in the form of direct derivation of the case, and cardiac and renal adverse events were collected through outpatient recorder system. All-cause death information was obtained from the Public Security and matched to the electronic Clinical Management System of the Guangdong Provincial People's Hospital records.
- Detailed Description
This is a single center, retrospective observation study collecting data on 88938 coronary angiography and / or coronary intervention patients from January 2007 to Decemeber 2018. Data regarding demographic information, admission diagnoses and history of present illness, biomarkers and details on preventive hydration and medications will be collected. The primary endpoint of this study is All-cause mortality, and secondary endpoints are Adverse Cardiovascular and Kidney Events.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 88938
- Patients referred to CAG or PCI;
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All-cause mortality From hospital admission to 13 years follow-up Admission Patients Died for all-cause mortality within 13 years.
- Secondary Outcome Measures
Name Time Method Contrast-Induced Acute Kidney Injury (CI-AKI 0.3) 48 hours defined as a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure
Cystatin C based CI-AKI (CI-AKI cyc) 24-48 hours Cystatin C based CI-AKI, defined as a ≥10% absolute increase in serum cystatin C during the first 24 hours after the procedure and and a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure.mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure
The change of eGFR, calculate based on CrCl and serum cystatin C 48-72 hours The eGFR creatinine-cystatin C was calculated by the 2012 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation: 135 \*min(Scr/κ, 1)α \* max(Scr/κ, 1)-0.601 \* min(Scys/0.8, 1)-0.375 \* max (Scys/0.8, 1)-0.711 \* 0.995Age \[\* 0.969 if female\] \[\* 1.08 if black\], where Scr is serum creatinine, Scys is serum cystatin C, κ is 0.7 for females and 0.9 for males, α is -0.248 for females and -0.207 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.
Contrast-induced Persistent kidney injury (CI-PKI) 3 months Serum creatinine was measured by endpoint colorimetry or enzymatic assays. CI-PKI was defined as residual impairment of renal function indicated by a ≥ 25% reduction in creatinine clearance at 3 months in comparison with baseline. comparison with baseline
Incidence of major adverse cardiovascular events 3-12months all-cause mortality (cardiovascular and noncardiovascular) and cardiovascular events.
Follow-up major adverse cardiovascular and clinical events 3-12months We will follow up the patients by telephone and outpatient service to know the one year all-cause mortality (cardiovascular and noncardiovascular) and cardiovascular events.
Trial Locations
- Locations (1)
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, Guangdong, China